The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events

Abstract

Abstract:Together with the use of novel oral targeted therapies, a multidisciplinary approach can be used to effectively treat patients with advanced pancreatic neuroendocrine tumours (pNETs). Here we review the integration of the oncology nurse to the newly developed oral treatment setting for patients with pNETs. From the outset, the nurse must be involved in various processes, including performance of baseline assessments (e.g. blood pathology, cardiac and lung function testing, patient history) and general medical observations, treatment administration, dietary guidance, evaluation of comorbidities, and review of concomitant medications. Patient education and establishment of a strong partnership in care before the start of pNET therapy ultimately increase treatment adherence and reduce potential toxicities. Regular review of general patient status and disease progression and continuous monitoring of adverse events also help enhance treatment outcomes and subsequently improve quality of life. Nurses' knowledge of agent-specific toxicities and prompt, proactive management is a critical aspect of care. In essence, as the pNET treatment landscape evolves, the role of the healthcare professional in overall patient care must shift accordingly.

Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature

“…Regardless of many demographic considerations, including gender, socioeconomic status and education level, the patients' difficulty in adhering to oral oncological agents has been well documented across tumor types, including solid tumors (gastrointestinal stromal tumors) [46], male breast cancer [47,48], pancreatic neuroendocrine tumors [49], non-small cell lung cancer [50] and renal cell cancer [51], in countries all across the world [52,53,54]. This has also been documented in hematological malignancies [2] including the whole age spectrum of CML patients: both younger [5] and older age groups [55].…”

Endocrine and associated consequences of conservative and chemo- and hormonal therapy in cancer treatment: opportunities and extent of the feasibility of correction.

“…Поскольку упомянутые таргетные препараты в сочетании, в частности, с аналогами сома-тостатина (октреотид и др.) или по самосто-ятельной схеме применяются и при нейроэн-докринных опухолях [33], это дополнительно расширяет круг больных, нуждающихся в кор-ригирующих мерах воздействия.…”